Measuring Alzheimer's disease progression with transition probabilities: Estimates from CERAD

Neurology

Volumn 57, Issue 6, 2001, Pages 957-964

  Neumann, P J ^a,e   Araki, S S ^a   Arcelus, A ^c   Longo, A ^c   Papadopoulos, G ^d   Kosik, K S ^b   Kuntz, K M ^a   Bhattacharjya, A ^d  

^a HARVARD CENTER FOR RISK ANALYSIS   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Analysis Group/Economics   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CHRONIC DISEASE; COMMUNITY CARE; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NEUROLOGIC DISEASE; NURSING HOME; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SURVIVAL RATE; SYMPTOMATOLOGY;

EID: 0035949761     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.6.957     Document Type: Article

References (47)

1. Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years' therapy using donepezil
2. An economic evaluation of donepezil in the treatment of Alzheimer's disease
3. Cost effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
4. Economic evaluation of donopezil for the treatment of Alzheimer's disease in Canada
5. Estimating the long term cost savings from the treatment of Alzheimer's disease: A modelling approach
6. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician
7. The Clinical Dementia Rating (CDR): Current version and scoring rules
8. Early-onset Alzheimer's disease: Clinical predictors of institutionalization and death
9. Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease. A CERAD analysis, part XII
10. Predicting time to nursing home care and death in individuals with Alzheimer's disease
11. The prognosis in Alzheimer's disease: "How far" rather than "how fast" best predicts the course
12. Monitoring progression in Alzheimer's disease
13. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease
14. A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration
15. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer's disease
16. Predictors of time to institutionalization of patients with Alzheimer's disease. The CERAD experience, part XVII
17. Behavioral disturbance in dementia of the Alzheimer's type
18. The spectrum of behavioral changes in Alzheimer's disease
19. The evolution of psychiatric symptoms in Alzheimer's disease: A natural history study
20. The course of psychopathologic features in mild to moderate Alzheimer disease
21. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer's disease
22. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
23. Psychosis and physical aggression in probable Alzheimer's disease
24. Incontinence and troublesome behaviors predict institutionalization in dementia
25. Nursing home placement is related to dementia progression
26. Sleep in Alzheimer's disease and the sundown syndrome
27. Sleep and degenerative neurologic disorders
28. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part I. Clinical and neuropsychological assessment of Alzheimer's disease
29. The behavior rating scale for dementia of the Consortium to Establish a Registry for Alzheimer's Disease
30. Regression models and life tables
31. Time until institutionalization and death in patients with dementia
32. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years
33. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
34. Natural history of Alzheimer's disease: Path-dependent evaluation of clinical and economic outcomes using decision database methodology
35. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
36. Advances in the treatment of behavioral disturbances in Alzheimer's disease
37. A 5-month, randomized placebo-controlled trial of galantamine in AD
38. The Markov process in medical prognosis
39. Markov models in medical decision making: A practical guide
40. Factors affecting decisions to institutionalize demented elderly
41. Factors determining the decision to institutionalize dementing individuals: A prospective study
42. The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD study
43. A prospective 5-year follow-up study on behavioral disturbances of community-dwelling elderly people with Alzheimer's disease
44. Cognitive function and the costs of Alzheimer's disease
45. Alzheimer's disease care: Costs and potential savings
46. Relation between severity of Alzheimer's disease and costs of caring
47. Health utilities in Alzheimer's disease: A cross-sectional study of patients and caregivers